You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 21, 2024

~ Buy the XENLETA (lefamulin acetate) Drug Profile, 2024 PDF Report in the Report Store ~

XENLETA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Xenleta patents expire, and when can generic versions of Xenleta launch?

Xenleta is a drug marketed by Nabriva and is included in two NDAs. There are three patents protecting this drug.

This drug has eighty-seven patent family members in thirty-four countries.

The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this compound. Additional details are available on the lefamulin acetate profile page.

DrugPatentWatch® Generic Entry Outlook for Xenleta

Xenleta was eligible for patent challenges on August 19, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 19, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for XENLETA
Drug Prices for XENLETA

See drug prices for XENLETA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for XENLETA
Generic Entry Dates for XENLETA*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
NDA:
Dosage:
SOLUTION;INTRAVENOUS
Generic Entry Dates for XENLETA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XENLETA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Nabriva Therapeutics AGPhase 1
Nabriva Therapeutics AGPhase 1/Phase 2
University of WashingtonPhase 1/Phase 2

See all XENLETA clinical trials

US Patents and Regulatory Information for XENLETA

XENLETA is protected by three US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of XENLETA is ⤷  Try a Trial.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting XENLETA

Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Process for the preparation of pleuromutilins
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting XENLETA

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nabriva XENLETA lefamulin acetate SOLUTION;INTRAVENOUS 211673-001 Aug 19, 2019 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Nabriva XENLETA lefamulin acetate TABLET;ORAL 211672-001 Aug 19, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Nabriva XENLETA lefamulin acetate SOLUTION;INTRAVENOUS 211673-001 Aug 19, 2019 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for XENLETA

When does loss-of-exclusivity occur for XENLETA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 08229609
Estimated Expiration: ⤷  Try a Trial

Patent: 11257938
Estimated Expiration: ⤷  Try a Trial

Austria

Patent: 23486
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0809023
Estimated Expiration: ⤷  Try a Trial

Patent: 2012029982
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 78795
Estimated Expiration: ⤷  Try a Trial

Patent: 99029
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1668738
Estimated Expiration: ⤷  Try a Trial

Patent: 3080083
Estimated Expiration: ⤷  Try a Trial

Patent: 4211624
Estimated Expiration: ⤷  Try a Trial

Patent: 5111117
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0110869
Estimated Expiration: ⤷  Try a Trial

Patent: 0220201
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 17482
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 37143
Estimated Expiration: ⤷  Try a Trial

Patent: 80874
Estimated Expiration: ⤷  Try a Trial

Patent: 76505
Estimated Expiration: ⤷  Try a Trial

Patent: 99356
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 8707
Estimated Expiration: ⤷  Try a Trial

Patent: 3273
Estimated Expiration: ⤷  Try a Trial

Patent: 0970868
Estimated Expiration: ⤷  Try a Trial

Patent: 1291370
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 72618
Estimated Expiration: ⤷  Try a Trial

Patent: 37143
Estimated Expiration: ⤷  Try a Trial

Patent: 80874
Estimated Expiration: ⤷  Try a Trial

Patent: 99904
Estimated Expiration: ⤷  Try a Trial

Patent: 76505
Estimated Expiration: ⤷  Try a Trial

Patent: 99356
Estimated Expiration: ⤷  Try a Trial

Finland

Patent: 0200038
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 40185
Estimated Expiration: ⤷  Try a Trial

Patent: 53006
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 35861
Estimated Expiration: ⤷  Try a Trial

Patent: 57587
Estimated Expiration: ⤷  Try a Trial

Patent: 100001
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 0440
Estimated Expiration: ⤷  Try a Trial

Patent: 2999
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 79114
Estimated Expiration: ⤷  Try a Trial

Patent: 93651
Estimated Expiration: ⤷  Try a Trial

Patent: 38021
Estimated Expiration: ⤷  Try a Trial

Patent: 01742
Estimated Expiration: ⤷  Try a Trial

Patent: 10522143
Estimated Expiration: ⤷  Try a Trial

Patent: 13528162
Estimated Expiration: ⤷  Try a Trial

Patent: 14159416
Estimated Expiration: ⤷  Try a Trial

Patent: 16210804
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 2020531
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 8916
Estimated Expiration: ⤷  Try a Trial

Patent: 4666
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 7176
Estimated Expiration: ⤷  Try a Trial

Patent: 12013645
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 314
Estimated Expiration: ⤷  Try a Trial

Patent: 332
Estimated Expiration: ⤷  Try a Trial

Netherlands

Patent: 1086
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 9011
Estimated Expiration: ⤷  Try a Trial

Patent: 3804
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 21002
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 37143
Estimated Expiration: ⤷  Try a Trial

Patent: 76505
Estimated Expiration: ⤷  Try a Trial

Patent: 99356
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 37143
Estimated Expiration: ⤷  Try a Trial

Patent: 80874
Estimated Expiration: ⤷  Try a Trial

Patent: 76505
Estimated Expiration: ⤷  Try a Trial

Patent: 99356
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 5104
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 37143
Estimated Expiration: ⤷  Try a Trial

Patent: 99356
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0905590
Estimated Expiration: ⤷  Try a Trial

Patent: 1208056
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1478593
Estimated Expiration: ⤷  Try a Trial

Patent: 1935333
Estimated Expiration: ⤷  Try a Trial

Patent: 090123882
Estimated Expiration: ⤷  Try a Trial

Patent: 130079406
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 75503
Estimated Expiration: ⤷  Try a Trial

Patent: 20459
Estimated Expiration: ⤷  Try a Trial

Patent: 59729
Estimated Expiration: ⤷  Try a Trial

Patent: 09198
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 06657
Estimated Expiration: ⤷  Try a Trial

Patent: 85073
Estimated Expiration: ⤷  Try a Trial

Patent: 0904402
Estimated Expiration: ⤷  Try a Trial

Patent: 1209026
Estimated Expiration: ⤷  Try a Trial

Tunisia

Patent: 09000347
Estimated Expiration: ⤷  Try a Trial

Patent: 12000506
Estimated Expiration: ⤷  Try a Trial

Turkey

Patent: 1802636
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 836
Estimated Expiration: ⤷  Try a Trial

Patent: 8378
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XENLETA around the world.

Country Patent Number Title Estimated Expiration
Peru 20020144 DERIVADOS DE PLEUROMUTILINAS COMO AGENTES ANTIBACTERIANOS ⤷  Try a Trial
Singapore 185104 PROCESS FOR THE PREPARATION OF PLEUROMUTILINS ⤷  Try a Trial
South Korea 20090123882 PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for XENLETA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2137143 2090054-4 Sweden ⤷  Try a Trial PRODUCT NAME: LEFAMULIN, SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/20/1457 20200728
2137143 CR 2020 00046 Denmark ⤷  Try a Trial PRODUCT NAME: LEFAMULIN, SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/20/1457 20200728
2137143 132020000000167 Italy ⤷  Try a Trial PRODUCT NAME: LEFAMULINA SUOI SALI E SOLVATI(XENLETA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1457, 20200728
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.